SABS
SAB Biotherapeutics Inc
2.90$
-1.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | +7.6% | -19.4% | -24.7% | +6.7% | -46.2% | -43.5% | -100.0% | – | -85.3% | +1,381.6% | -75.9% | +209.7% | -72.1% | -100.2% | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | +46.2% | -97.8% | +2,493.1% | +25.1% | -35.6% | -89.4% | – | – | -3.3% | +10.4% | -4.2% | +110.2% | -48.5% | -5.4% | -18.7% | +874.6% | -89.3% | -6.9% | -0.3% | -1.4% | – | – | |
| – | – | – | -111.4% | – | -97.1% | -470.7% | – | – | – | – | – | – | -326.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +46.2% | -19.6% | -29.2% | +25.1% | -35.6% | -14.6% | -2.6% | -36.8% | -19.3% | +10.5% | +6.9% | +89.1% | -16.3% | +15.2% | -2.6% | +0.4% | -8.6% | +27.9% | +19.9% | +24.7% | +20.9% | – | |
| – | – | – | -28.0% | +50.1% | +115.3% | -33.1% | -16.9% | -6.2% | -28.7% | +19.6% | -15.9% | -11.3% | +478.8% | -71.9% | -13.0% | -4.5% | -23.2% | +16.6% | -12.2% | +35.6% | +35.9% | +30.9% | +9.2% | – | |
| – | – | – | -28.0% | +661.3% | -57.5% | -33.1% | -16.9% | +143.4% | -25.1% | -10.2% | -19.7% | -1.1% | +225.3% | -43.2% | -8.8% | +9.5% | -9.7% | -66.6% | +186.1% | +33.7% | +26.0% | +28.2% | +21.5% | – | |
| – | – | – | -452.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -1.0% | +5.5% | +274.8% | -75.5% | -1.1% | -0.9% | +24.2% | +5.3% | -18.5% | -7.5% | +11.7% | -1.9% | +21.9% | -16.2% | -9.2% | -1.8% | -7.5% | -32.7% | +46.6% | -1.1% | -1.2% | – | |
| – | – | – | -308.7% | – | – | – | -551.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | -137.1% | – | – | – | |
| – | – | – | +2.9% | -106.1% | – | -68.7% | -200.0% | – | – | +0.0% | +193.9% | +121.6% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -308.7% | – | – | – | -584.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | -137.1% | – | – | – | |
| – | – | – | -248.0% | – | – | – | -321.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | -134.7% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.